Nintedanib Stada (Nintedanib)

Nintedanib is indicated for fibrotic lung diseases and certain oncologic conditions, acting on pathways that drive fibroblast proliferation and tumor angiogenesis.

• Idiopathic pulmonary fibrosis: slows disease progression, reduces decline in forced vital capacity and may improve quality of life in adult patients.
• Systemic sclerosis‑associated interstitial lung disease: improves forced vital capacity, delays respiratory deterioration and supports functional status in affected individuals.
• Non‑small cell lung cancer: used together with standard chemotherapy to inhibit tumor growth, angiogenesis and may extend progression‑free survival.

• Nintedanib blocks the intracellular kinase activity of multiple receptor tyrosine kinases, including vascular endothelial growth factor receptors (VEGFR 1‑3), platelet‑derived growth factor receptors (PDGFR‑α/β) and fibroblast growth factor receptors (FGFR 1‑3). By inhibiting these pathways, it reduces endothelial cell proliferation, fibroblast activation, extracellular matrix deposition and angiogenesis, thereby limiting fibrotic remodeling in the lung and tumor vascularization.

Nintedanib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Diarrhea: frequent loose stools that may be mild to moderate.
• Nausea: feeling of sickness often accompanied by loss of appetite.
• Vomiting: occasional episodes of stomach emptying.
• Decreased appetite: reduced desire to eat leading to weight loss.
• Abdominal pain: discomfort or cramping in the stomach area.
• Elevated liver enzymes: mild increases in ALT/AST observed in laboratory tests.

Serious or Rare Side Effects

• Hepatic failure: severe liver injury requiring medical attention.
• Severe bleeding: gastrointestinal or intracranial hemorrhage.
• Arterial thromboembolism: clot formation in arteries causing ischemic events.
• Gastrointestinal perforation: hole formation in the stomach or intestines.
• Severe hypertension: markedly high blood pressure needing urgent care.
• Serious infection: opportunistic infections in immunocompromised patients.

When prescribing Nintedanib, clinicians should consider several safety measures to minimize risk.

• Liver function monitoring: assess baseline ALT/AST and repeat regularly during therapy.
• Bleeding risk assessment: evaluate history of hemorrhage and avoid concomitant anticoagulants when possible.
• Cardiovascular evaluation: monitor blood pressure and manage hypertension before and during treatment.
• Drug interaction review: check for strong CYP3A4 modulators that may alter drug exposure.
• Contraindication in severe hepatic impairment: avoid use in patients with Child‑Pugh class C liver disease.
• Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Nintedanib interacts with several medicines; understanding the level of interaction guides clinical decisions.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase nintedanib exposure and toxicity.
• Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy by lowering drug levels.
• Anticoagulants (e.g., warfarin) and antiplatelet agents (e.g., aspirin): heightened risk of serious bleeding.
• P‑glycoprotein inhibitors (e.g., verapamil): can raise plasma concentrations.
• High‑dose statins (e.g., simvastatin 80 mg): increased risk of liver enzyme elevation.

Moderate Interactions (Monitor Closely)

• Moderate CYP3A4 inhibitors (e.g., erythromycin, fluconazole): may modestly raise nintedanib levels.
• Moderate CYP3A4 inducers (e.g., phenobarbital, phenytoin): may modestly decrease drug exposure.
• NSAIDs (e.g., ibuprofen): additive gastrointestinal bleeding risk.
• Diuretics (e.g., furosemide): monitor electrolytes and renal function.
• Proton pump inhibitors: may affect absorption, observe for reduced efficacy.